HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.

Abstract
The aim of this multicenter, prospective, longitudinal phase IV study was to establish the optimal duration of neoadjuvant letrozole that would allow breast conservation surgery (BCS) in patients with early breast cancer who were initially unsuitable. Primary, invasive, estrogen-receptor- and/or progesterone-receptor-positive breast cancer patients, with large tumors (≥T2 i.e., >20 mm) not initially suitable for BCS, received 2.5 mg letrozole p.o. daily. Patients continued treatment until they became eligible for BCS, progressed, failed to meet criteria for BCS and withdrew for scheduled mastectomy, withdrew for other reasons, or completed 12 months of letrozole treatment without a BCS decision being made. A total of 146 patients were enrolled; seven patients who did not have a valid postbaseline tumor assessment were excluded from the final efficacy analysis. At study closure, 69 % of patients (96 of 139) were eligible for BCS. The median time to achieve a tumor response sufficient to allow BCS with neoadjuvant letrozole was 7.5 months (95 % CI 6.3-8.5 months). Letrozole was well tolerated, and most adverse events were mild-to-moderate (grade 1-2). The results from this trial suggest that extended letrozole therapy in the neoadjuvant setting (7.5 months), as opposed to conventional treatment of 4 months, is optimal to achieve maximum reduction in tumor volume sufficient for BCS.
AuthorsRobert Carpenter, Julie C Doughty, Carolyn Cordiner, Nuala Moss, Ashu Gandhi, Chris Wilson, Chris Andrews, Gillian Ellis, Gerald Gui, Anthony I Skene
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 144 Issue 3 Pg. 569-76 (Apr 2014) ISSN: 1573-7217 [Electronic] Netherlands
PMID24562823 (Publication Type: Clinical Trial, Phase IV, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Aromatase Inhibitors
  • Nitriles
  • Triazoles
  • letrozole
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Aromatase Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Breast Neoplasms (diagnosis, drug therapy, mortality, surgery)
  • Female
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Grading
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Nitriles (administration & dosage, adverse effects, therapeutic use)
  • Time Factors
  • Treatment Outcome
  • Triazoles (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: